Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2265-2268

  Kodaira, Takeshi ^a   Fuwa, Nobukazu ^a   Tachibana, Hiroyuki ^a   Hidano, Satoshi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Head and neck; Nedaplatin; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BILIRUBIN; NEDAPLATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; TEGAFUR;

EID: 33745557777     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955, 2000.
2. Martin M, Hazan A, Vergnes L, Peytral C, Mazeron JJ, Senechaut JP, Lelievre G and Peynegre R: Randomized study of 5 fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: a preliminary report. Int J Radiat Oncol Biol Phys 19: 973-975, 1990.
3. Rich TA, Shepard RC and Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22: 2214-2232, 2004.
4. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M and Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
5. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K and Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005.
6. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
7. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B and S-1 Cooperative Study Group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390, 2001.
8. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y and Sugita M: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93: 884-889, 2005.
9. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S and Ota K: An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19: 863-869, 1992.
10. Fuwa N, Kodaira T, Kamata M, Matsumoto A, Furutani K, Tachibana H and Ito Y: Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol 25: 565-569, 2002.
11. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
12. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145, 2000.
13. Ichinose Y, Yoshimori K, Sakai H, NAkai Y, Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10: 7860-7864, 2004.
14. Sato N, Sato Y, Saeki T and Sano M: The cumulative dose of previous treatment does not relate to efficacy of S-1 in patients with taxane resistant breast cancer. San Antonio Breast Cancer Symposium #1078, 2004.
15. Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Sugihara M, Ina K, Kusugami K and Goto S: A phase II multicentric trial of S-1 combined with 24-h infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 25: 1297-1301, 2005.
16. Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, Yoshizaki N and Niitsu Y: A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol 10: 40-44, 2005.
17. Fujii M, Endo S, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Yamane H, Fujii H, Honma A and Tomita T: A phase I/II study of S-1 plus cisplatin (CDDP) in patients with head and neck cancer (HNC). Proc Am Soc Clin Oncol 24: 513, 2005. (Abstr.5552).